CXCL9 and neoplasm: Cxcr3, a chemokine receptor with anti-tumor effects expressed in effector CD8+ T cells, Th1 cells, and NK cells, interacts with its ligands Cxcl9, Cxcl10, and Cxcl11, promoting immune cell recruitment to TME [41, 42].